Table 1 Characteristics of the study and control groups
From: Impact of comorbidities on risk of angioedema without urticaria in elderly patients
Study group, n = 242 | Control group, n = 263 | ASD | |
|---|---|---|---|
Mean age (range; in years) | 68.3 (60–88) | 65.9 (60–91) | 0.120 |
Mean BMI (kg/m2) ± SD | 24.1 ± 6.4 | 27.2 ± 5.8 | 0.151 |
Female (%) | 138 (57) | 152 (58) | 0.006 |
Rural area (%) | 115 (48) | 140 (53) | 0.081 |
Smoker or former smoker (%) | 97 (40) | 99 (37) | 0.012 |
Comorbidities (%) | |||
One chronic disease | 65 (27) | 74 (28) | 0.181 |
Two chronic diseases | 110 (45) | 121 (46) | 0.176 |
> Two chronic diseases | 67 (28) | 83 (32)* | 0.048 |
No. of angioedema incidences (%) | – | – | |
One | 54 (22) | ||
Two to five | 161 (67) | ||
Six or more (recurrent) | 27 (11) | ||
Emergency intervention | 48 (20) | – | – |
Hospitalization due to angioedema | 63 (26) | ||
Mean time of onset in minutes (range) | 18 min (2–129) | ||
Localization | |||
Mouth | 179 (74) | ||
Eye area | 104 (43) | ||
Throat | 62 (26) | ||
Hands or feet | 75 (31) | ||
Respiratory tract | 32 (13) | ||
Digestive tract | 29 (12) | ||
Others | 19 (8) | ||
Symptomatic medications used to treat angioedema (%) | – | – | |
Antihistamines | 219 (90) | ||
Adrenaline | 17 (7) | ||
Systemic steroids | 114 (47) | ||
Calcium | 176 (73) | ||
Montelukast | 51 (21) | ||
Tranexamic acid | 11 (5) | ||
Blood plasma | 2 (1) | ||